Zobrazeno 1 - 10
of 52
pro vyhledávání: '"R. G. Townley"'
Autor:
Jonathan A. Bernstein, L. A. Hanby, Robert A. Nathan, T. Montanaro, Anjuli Nayak, Joseph H. Butterfield, R. G. Townley, J. A. Colton, S. Chodosh, Michael Schatz, Z. M. Munk, A. C. DeGraff, P. V. Williams, J. R. Taylor, T. B. Edwards, D. L. Southern, Paul H. Ratner, C. A. Bruce, T. D. Bell, M. Cohen, A. Floreani, William J. Calhoun, J. P. Kemp, S. Pollard, S. C. Campbell, L. Kirby, S. Weiss, T. W. Littlejohn, D. Auerbach, S. A. Gillman, S. P. Galant, J. W. Kylstra, S. R. Hirsch, William E. Berger, C. M. Bonuccelli, H. J. Schwartz, R. V. Albery, Frank C. Hampel, L. A. Weiss, Sheldon L. Spector, D. M. Lang, L. J. Rossoff, M. S. Rowe, T. J. Chu, P. J. Hannaway, D. Q. Mitchell, D. W. Aaronson, R. J. Dockhorn, J. P. O'Connor, Stanley Goldstein, Leonard Bielory
Publikováno v:
Journal of Allergy and Clinical Immunology. 102:935-942
Previous trials demonstrated the effectiveness of the leukotriene receptor antagonist zafirlukast in patients with mild-to-moderate asthma.We sought to assess the efficacy and safety of zafirlukast and its effect on patients' quality of life (QOL) du
Publikováno v:
Autonomicautacoid pharmacology. 31(3-4)
1 Levels of IL-13, IL-1β and TNF-α are increased in bronchial lavage fluid of asthmatics and induce certain significant features of bronchial asthma including airway hyper-responsiveness (AHR). In this study, we have investigated the effect of thes
Autor:
R G, Townley
Publikováno v:
Journal of clinical pharmacology. 39(3)
Publikováno v:
Immunopharmacology. 31(2-3)
It has been suggested that interleukin-4 and -5 (IL-4 and IL-5) are instrumental in the control of allergic disease. Elevated levels of IL-4 messenger RNA (mRNA) have been detected in numerous foci of atopic activity, including bronchoalveolar lavage
Publikováno v:
Journal of lipid mediators and cell signalling. 10(3)
Platelet-activating factor (PAF), an inflammatory mediator, induces microvascular leak, eosinophil chemotaxis, and possibly increases non-specific bronchial hyperresponsiveness in humans. PAF antagonists may have clinical benefits in asthma.We determ
Publikováno v:
Annals of allergy. 73(2)
Second generation antihistamines have been reported to have anti-inflammatory properties in addition to their potency as H1 antagonists. In this in-vitro study, we evaluated the effect of terfenadine on platelet activating factor-(PAF)-induced or N-f
Autor:
M M, Khan, R G, Townley
Publikováno v:
Proceedings of the Western Pharmacology Society. 37
Publikováno v:
Annals of allergy. 71(4)
We investigated the effects of interleukin-3 (IL-3) on histamine release (direct releasing and indirect enhancing effects) from basophils in allergic asthmatic subjects. Interleukin-3 caused direct histamine release (HR) in selected donors (IL-3 resp
Publikováno v:
Annals of allergy. 71(4)
We investigated neutrophil density change by platelet activating factor or granulocyte-macrophage colony-stimulating factor (GM-CSF). Although PAF significantly converted neutrophil density, there was no significant difference in density change betwe
Publikováno v:
Annals of allergy. 71(4)
We investigated the in vitro effect of loratadine, a new nonsedating H1 histamine antagonist, on the eosinophil functions of chemotaxis, superoxide anion (O2-) generation and eosinophil cationic protein (ECP) release, using purified eosinophils obtai